key: cord-1055454-u2c5lm1g authors: Anand, Pria; Slama, Michaël C. C.; Kaku, Michelle; Ong, Charlene; Cervantes‐Arslanian, Anna M.; Zhou, Lan; David, William S.; Guidon, Amanda C. title: COVID‐19 in patients with myasthenia gravis date: 2020-05-22 journal: Muscle Nerve DOI: 10.1002/mus.26918 sha: d425a19b5be6a6c57e860ac4d317592ed90c6213 doc_id: 1055454 cord_uid: u2c5lm1g INTRODUCTION: Coronavirus disease 2019 (COVID‐19) has rapidly become a global pandemic, but little is known about its potential impact on patients with myasthenia gravis (MG). METHODS: We studied the clinical course of COVID‐19 in five hospitalized patients with autoimmune MG (four with acetylcholine receptor antibodies, one with muscle‐specific tyrosine kinase antibodies) between April 1, 2020‐April 30‐2020. RESULTS: Two patients required intubation for hypoxemic respiratory failure, whereas one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID‐19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications. DISCUSSION: Our findings suggest that the clinical course and outcomes in patients with MG and COVID‐19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population. T A B L E 1 Patients' characteristics 3 | RESULTS Infections are a common trigger for myasthenic exacerbations. 10 In addition to the risk of myasthenic exacerbation from COVID- hydroxychloroquine may also trigger a myasthenic exacerbation. 14, 15 Unless azithromycin and hydroxychloroquine become standard of care for COVID-19, they should likely be avoided or used with caution in patients with MG given the potential to worsen MG. 16 Tocilizumab, a humanized interleukin-6 receptor monoclonal antibody, is also used experimentally in severe cases of COVID-19. 2 Patient 1, who had a history of myasthenic crisis, received tocilizumab for COVID-19 and was extubated and discharged without clear evidence of a myasthenic exacerbation. Interleukin-6 stimulates the production of autoantibodies from plasma cells, and tocilizumab has shown efficacy in the treatment of some autoantibody-mediated disorders. 17 In gravis. 23 A large registry is needed because, as illustrated by the patients described in this series, outcomes in smaller groups can be highly variable. The authors thank Shibani Mukerji MD, PhD, of Massachusetts General Hospital for her leadership and for facilitating this and other collaborations among neurologists during the COVID-19 pandemic. Effective treatment of severe COVID-19 patients with tocilizumab Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in downtown Los Angeles A first case of meningitis/encephalitis associated with SARS-coronavirus-2 COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features Encephalitis as a clinical manifestation of COVID-19 Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic Factors associated with acute exacerbations of myasthenia gravis Care for critically ill patients with COVID-19 Intubation and vVentilation amid the COVID-19 outbreak Volume Myasthenia gravis and infectious disease The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab First cases of COVID-19 in heart transplantation from Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient Findings of acute pulmonary embolism in COVID-19 patients Associated Risks and Effects in Myasthenia Gravis (CARE-MG) Registry. International Myasthenia Gravis/COVID-19 Working Group and the Myasthenia Gravis Rare Disease Network International consensus guidance for management of myasthenia gravis: executive summary How to cite this article COVID-19 in patients with myasthenia gravis The authors declare no potential conflicts of interest. We confirm that we have reviewed the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. https://orcid.org/0000-0002-7421-7750Amanda C. Guidon https://orcid.org/0000-0003-0843-2935